Drug companies told to tackle antibiotics threat

Drug companies should agree to "pay or play" in the urgent race to develop new antibiotics to tackle a global threat of antimicrobial resistance (AMR), says a review commissioned by the British government.

Led by former Goldman Sachs chief economist Jim O'Neill, the review says every sector affected by the growing threat of superbug infections - from patients, to doctors, to governments, to the healthcare industry - must be forced "out of its comfort zone" if the issue is to be successfully tackled